ESOT 2013: Outcomes with tacrolimus-based immunosuppression after kidney transplantation with standard or extended-criteria donor organs: the OSAKA study
Bernhard Banas, Regensburg, Germany – Prolonged-release tacrolimus administered once-daily provides high rates of graft survival and reduction in biopsy-confirmed acute rejection (BCAR), with a manageable tolerability profile, in patients… read more.